---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047566"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:50:39.091242+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3

## Summary
- Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.
- Cash $4.6M at March 31, 2025, up from $3.7M at year-end 2024 after two offerings raising ~$3.6M gross.
- Closed $2.5M registered direct offering in Jan 2025 and $1.1M offering in Mar 2025; $12M Lincoln Park equity line closed in May.
- Received positive EMA regulatory guidance for ibezapolstat Phase 3 program, aligned with FDA, confirming MAA pathway.
- Japanese and Indian patent offices granted new DNA polymerase IIIC inhibitor patents expiring Dec 2039 for ACX-375C.

## SEC filing metadata
- accession: 0001104659-25-047566
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/0001104659-25-047566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925047566/tm2514876d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047566
- JSON: https://secwatch.observer/filing/0001104659-25-047566.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.